HRT and Antidepressants: Can You Take Both?

Yes—HRT and antidepressants can be prescribed at the same time. That is not a class-wide safety clearance: the exact hormone product and route, antidepressant, other medicines such as tamoxifen or CYP1A2 inhibitors, and your medical and psychiatric history determine the review. Do not stop or taper an antidepressant without its prescriber.

Best for you if: you take an antidepressant and want hormones added · you were handed an antidepressant when you expected a menopause conversation · you started HRT and cannot tell what is causing what · you want to know which exact drug names change the answer.

Not enough on its own if: you are having thoughts of harming yourself · you have possible mania, hypomania, psychosis, or a history of bipolar disorder that has not been reviewed · you take tamoxifen · you have unexplained bleeding after menopause · you need a personalized dose, taper, or interaction clearance. Those need a person, not a page.

If you are not safe right now: call or text 988 in the United States. The 988 Suicide & Crisis Lifeline is free and confidential. Call 911 if you are in immediate danger. Please do that before you read the rest of this.^[1]

Your answer in 7 checks

Check	Why it changes the answer	The question to bring
1. Exact hormone product and route	“HRT” can mean systemic oral or transdermal estrogen, low-dose vaginal estrogen, estrogen alone, or estrogen with a progestogen. Those are not one exposure or one clinical job.	“What exact product and route are you proposing, and what symptom is it treating?”
2. Exact antidepressant and indication	The same antidepressant may be used for major depression, anxiety, pain, sleep, or menopausal hot flashes. “Is it working?” means something different in each case.	“What was this prescribed to treat, and do I still have that problem?”
3. Tamoxifen	Paroxetine has an explicit label-level warning about possible reduction in tamoxifen effectiveness. Fluoxetine and bupropion are also strong CYP2D6 inhibitors and belong in an oncology/pharmacist review.[2][3]	“Does my antidepressant affect tamoxifen activation?”
4. Fluvoxamine if Veozah is being considered	Veozah is contraindicated with any CYP1A2 inhibitor. Fluvoxamine is a strong CYP1A2 inhibitor; in the label study, it raised fezolinetant total exposure by 840%.[4][5]	“I take fluvoxamine. Does that rule out Veozah?”
5. CYP3A4 inhibitors or inducers	Current oral estradiol labeling says CYP3A4 inhibitors or inducers may change estrogen exposure. St. John’s wort is named directly; FDA’s current examples also classify nefazodone as a strong CYP3A inhibitor and fluvoxamine as a weak one.[5][6]	“Does anything on my full list change CYP3A4?”
6. Mood-safety history	Depression, antidepressant activation, withdrawal, mania, and hormone-regimen effects can overlap. Possible mania or unsafe thoughts outrank the hormone question.[7]	“What mood change means I call the same day?”
7. A written follow-up plan	Starting or changing two prescriptions without a baseline can leave you unable to tell what helped, what hurt, or what needs changing.	“Who owns follow-up, on what date, and what are we measuring?”

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

Why are women searching for HRT and antidepressants?

Answer: Most women are not asking a pure drug-interaction question. They are trying to decide whether menopause, depression, withdrawal, medication side effects, or more than one cause explains what changed—and whether the next step is HRT, psychiatric care, a medication review, or coordinated care.

The same search phrase hides four different trigger moments:

1. The appointment that went sideways. You described rage, brain fog, broken sleep, and a body that suddenly feels unfamiliar. You left with an SSRI prescription and no menopause conversation.
2. The addition. You have been steady on an antidepressant for years. Now you are sweating through your shirt at work, waking at 3 a.m., or dealing with painful sex—and you want HRT without destabilizing what already works.
3. The subtraction. You started HRT, you feel more like yourself, and now you want to know whether the antidepressant is still necessary.
4. The it-did-not-work. Months in, the symptom you cared about is still there. Or a new problem—flat mood, sweating, insomnia, sexual dysfunction—has appeared, and you cannot tell which medicine owns it.

All four type the same words: HRT and antidepressants.

So this page answers the safety question first, then the harder question underneath it: which treatment is doing which job, which exact drug names create a real flag, and who should own the next decision?

What we are not doing is telling you that your diagnosis was wrong or that you should stop anything. We are showing you where the labels are clear, where the evidence has boundaries, and where a page has to hand the decision back to your prescriber or pharmacist.

---

Can you take HRT and antidepressants together?

Answer: Yes, HRT and antidepressants can be part of the same treatment plan. There is no class-wide rule that prohibits every combination—but “HRT” and “antidepressant” each cover many products, routes, doses, and indications, so the exact pair and the rest of your medication list still need review.

The most reassuring fact in the current oral estradiol label is narrower than the internet usually makes it sound.

The label says estrogens are partly metabolized by CYP3A4. It gives examples of substances that can speed that pathway up, including St. John’s wort, phenobarbital, carbamazepine, and rifampin, and examples that can slow it down, including clarithromycin, ketoconazole, itraconazole, ritonavir, and grapefruit juice.^[6]

No prescription antidepressant appears among those named examples.

That is useful. It is not a universal clearance.

FDA describes its separate CYP interaction table as an optional list of examples, not a comprehensive list, and says it does not cover every possible interaction mechanism.^[5] A label’s named examples are not “the official list of everything this medicine bumps into.” They are one part of a full medication review.

What “not named” does—and does not—mean

It means the oral estradiol label does not single out common prescription antidepressants such as sertraline, escitalopram, fluoxetine, paroxetine, bupropion, or venlafaxine in its CYP3A4 examples.

It does not mean:

• every estrogen product has identical interaction language;
• every route creates the same exposure;
• no antidepressant affects any relevant enzyme;
• the antidepressant cannot interact with a third medicine;
• shared adverse effects cannot make the combination hard to tolerate;
• a page can clear your complete list.

The biggest documented medication flag on this page is not an estrogen–antidepressant pairing at all. It is tamoxifen plus certain CYP2D6-inhibiting antidepressants. The most absolute contraindication is also not an HRT interaction: it is Veozah plus a CYP1A2 inhibitor such as fluvoxamine.

That is why categories are not enough. Your labels matter.

Systemic and vaginal estrogen are different questions

Systemic hormone therapy—oral tablets, transdermal patches, gels, sprays, and some rings—reaches the bloodstream at levels used for whole-body symptoms such as hot flashes. Low-dose vaginal estrogen is used primarily for genitourinary symptoms such as vaginal dryness and painful sex, with much lower systemic exposure.^[8]

A woman using a low-dose vaginal insert for painful sex is not asking the same interaction question as a woman starting oral estradiol for night sweats. Put the exact product and route on the list.

If you have a uterus and are considering systemic estrogen, endometrial protection also belongs in the treatment plan. The mood and tolerability question may involve the progestogen as much as the estrogen.

FDA-approved and compounded HRT must stay separated

FDA-approved hormone products have standardized prescribing information, manufacturing requirements, strengths, and adverse-reaction reporting. Compounded hormone preparations are not FDA-approved, and FDA says it does not have evidence that compounded “bioidentical” hormones are safe and effective or safer or more effective than FDA-approved hormone therapy.^[9]

That does not make every compounded prescription automatically wrong. It does mean you cannot borrow the FDA label of an approved estradiol or progesterone product and pretend it clears a different compounded mixture.

For a compounded product, write down:

• every ingredient;
• the strength of each ingredient;
• the route;
• the compounding pharmacy;
• the prescriber’s reason for using it;
• whether an FDA-approved option was available.

The damaging admission on the safety question

No interaction table on this page can declare your combination safe.

That is not a disclaimer pasted on after the useful part. It is the useful part.

The FDA’s own CYP table says it is not comprehensive. Product labels change. A third prescription, an over-the-counter pain medicine, a supplement, a cancer drug, a seizure history, or a bipolar history can matter more than the pair you typed into search.

The win is not a green check mark. The win is arriving with the exact names and the right question so the person who can see your whole list can answer it properly.

---

Which antidepressants actually change the estrogen interaction review?

Answer: St. John’s wort is the clearest direct estrogen-label flag because current oral estradiol labeling names it as a CYP3A4 inducer that may lower estrogen concentrations, reduce effect, or change bleeding. Fluvoxamine and nefazodone touch the same CYP3A pathway in FDA’s examples table, but the reviewed estradiol label does not quantify their clinical effect on estrogen.

We built the ledger below by placing two primary sources side by side: the CYP3A4 pathway in current oral estradiol labeling and FDA’s current examples of CYP inhibitors, inducers, and substrates. It is an assembled review aid—not a drug-interaction clearance.

The Antidepressant × Estrogen Review Ledger

Assembled and last verified: August 2026

Medication	What FDA’s CYP examples table says	What the reviewed oral estradiol label says	The decision-level takeaway
Sertraline (Zoloft)	Weak CYP2D6 inhibitor; no CYP3A inhibitor or inducer classification in the table reviewed	Not one of the named CYP3A4 examples	No direct CYP3A flag found in these two sources. Review the full list rather than translating that into “zero interaction.”
Escitalopram (Lexapro)	Weak CYP2D6 inhibitor; no CYP3A inhibitor or inducer classification in the table reviewed	Not one of the named CYP3A4 examples	Same narrow answer: no direct CYP3A flag in these sources, not a personal clearance.
Citalopram (Celexa)	Not listed in the current FDA examples table	Not one of the named CYP3A4 examples	Absence from an examples table is not proof of no interaction. Use the product label and full-list review.
Venlafaxine (Effexor XR)	R-venlafaxine is listed as a sensitive CYP2D6 substrate; S-venlafaxine as a moderately sensitive CYP2D6 substrate	Not one of the named CYP3A4 examples	Its better-established menopause relevance is evidence for hot-flash treatment, not a direct estradiol CYP3A warning.
Desvenlafaxine (Pristiq)	Not listed in the current FDA examples table	Not one of the named CYP3A4 examples	Check the current desvenlafaxine label and the complete list; do not infer from omission.
Duloxetine (Cymbalta)	Moderate CYP2D6 inhibitor and sensitive CYP1A2 substrate	Not one of the named CYP3A4 examples	Not a direct estrogen-pathway flag in these sources. Other medicines that affect CYP1A2 can still matter to duloxetine.
Fluoxetine (Prozac)	Strong CYP2C19 and CYP2D6 inhibitor	Not one of the named CYP3A4 examples	The priority flag is tamoxifen, not a proven direct estradiol interaction.
Paroxetine (Paxil; Brisdelle)	Strong CYP2D6 inhibitor	Not one of the named CYP3A4 examples	Current paroxetine/Brisdelle labeling carries the clearest tamoxifen warning on this page.[2]
Bupropion (Wellbutrin)	Strong CYP2D6 inhibitor	Not one of the named CYP3A4 examples	Tamoxifen belongs in the review. Bupropion’s dose-related seizure warning also matters if another proposed drug carries seizure cautions.[10]
Fluvoxamine (Luvox)	Strong CYP1A2 and CYP2C19 inhibitor; weak CYP3A, CYP2C9, and CYP2D6 inhibitor	Not one of the named CYP3A4 examples	No quantified estradiol effect in the reviewed sources. Veozah is contraindicated because fluvoxamine is a CYP1A2 inhibitor.[4]
Nefazodone	Strong CYP3A inhibitor	Not one of the named CYP3A4 examples	It touches the pathway named by the estrogen label. The effect on estrogen exposure is not quantified here, so ask rather than assume. It also affects Lynkuet’s CYP3A4 decision.
St. John’s wort	Strong CYP3A inducer; FDA notes the effect varies by preparation	Named directly as an inducer that may lower estrogen concentrations, reduce therapeutic effect, or change bleeding	Say it out loud even if nobody asks. “Natural” does not mean invisible to the interaction review.

Source: current FDA CYP interaction examples and current oral estradiol prescribing information. FDA says its examples table is a guide, not a comprehensive list.^[5][6]

The honest limit—and why we are telling you

This ledger is stronger than “they are all fine together” because it shows the exact pathway and the exact classifications.

It is also less dramatic than “these four antidepressants dangerously interact with estrogen,” because the documents do not establish that.

The current oral estradiol label flags CYP3A4 as a pathway. FDA’s examples table classifies nefazodone as a strong CYP3A inhibitor and fluvoxamine as a weak one. But the sources reviewed here do not give a measured estradiol exposure change for either drug.

That distinction matters. A pathway flag is a reason to ask. It is not a result we are allowed to invent.

Your first micro-commitment

Before your next appointment, copy the exact generic names from every label into one note:

• hormone product and route;
• antidepressant and dose;
• tamoxifen or other cancer treatment;
• prescriptions from other clinicians;
• aspirin, NSAIDs, anticoagulants, and migraine medicines;
• sleep aids;
• supplements, especially St. John’s wort;
• date of the latest start, stop, or dose change.

Do not write “HRT + antidepressant.” That hides the information the answer depends on.

---

Was I wrong to be given an antidepressant instead of HRT?

Answer: Not from the prescription alone. Current NICE guidance says to consider HRT for depressive symptoms that do not meet criteria for depression and began around the same time as other menopause symptoms; when depression is suspected or diagnosed, it says to use menopause and depression guidance together. A U.S. expert-panel guideline keeps antidepressants and psychotherapy front-line for perimenopausal depression.^[11][12]

This is where the “HRT or antidepressants?” argument usually becomes too simple to help anyone.

You may have read that antidepressants are the wrong treatment for menopause. You may also have been told that mood symptoms in midlife are depression and hormones have nothing to do with them.

Both statements can miss the person standing in the middle.

The real boundary is diagnosis plus indication—not country versus country

The current NICE guideline, last updated in April 2026, draws a line between:

• depressive symptoms below the threshold for a depression diagnosis that begin alongside other menopause symptoms; and
• suspected or diagnosed depression, which should be managed with depression guidance as well as menopause guidance.^[11]

The U.S. perimenopausal-depression guideline reaches a compatible boundary. It says antidepressants and psychotherapy are proven front-line treatments for perimenopausal depression. It also says estrogen is not FDA-approved to treat perimenopausal depression, while evidence suggests antidepressant effects in some perimenopausal women—particularly when vasomotor symptoms are present. The panel concluded that estrogen did not treat depressive disorders in postmenopausal women, and that evidence for estrogen plus progestogen was sparse and inconclusive.^[12]

So no: two national guidelines do not simply “disagree.”

Menopause-linked depressive symptoms below the diagnostic threshold and major depression are not the same treatment question.

The Diagnosis × Stage × Symptom Target Matrix

Your situation	What the evidence supports	What to ask next
Still cycling; low mood began with hot flashes, cycle changes, or other menopause symptoms; symptoms do not meet depression criteria	NICE says HRT can be considered for these depressive symptoms. The U.S. guideline identifies a possible antidepressant effect of estrogen in selected perimenopausal women.	“Do these symptoms meet criteria for depression, or are we treating a menopause-linked symptom cluster?”
Perimenopausal with diagnosed major depression	Antidepressants and psychotherapy remain front-line. HRT may still have a separate role for VMS or another menopause indication.	“Which treatment is aimed at the depression, and which is aimed at the menopause symptoms?”
Postmenopausal with a depressive disorder	The U.S. guideline did not support estrogen as a treatment for the depressive disorder. HRT may still treat hot flashes, GSM, or another approved menopause indication.	“What is the hormone supposed to treat if it is not the depression?”
Hot flashes without depression	Systemic hormone therapy is the most effective treatment when appropriate; selected nonhormonal medicines, including some antidepressants, also work.[13]	“What are my hormonal and nonhormonal choices for VMS?”
Depression or anxiety plus disruptive VMS	Both problems can be real and can require different treatments.	“Can we write down the target symptom for each prescription?”
Symptoms began after a dose, route, brand, or medication change	Timing becomes a major part of the assessment.	“What changed immediately before this started?”
Possible mania, psychosis, or unsafe thoughts	Mental-health safety comes first.	“Who can assess this today?”

So—were you fobbed off?

Sometimes a menopause assessment was missed. Sometimes the antidepressant was a sound treatment. Sometimes both are true: the prescription made sense, but it did not finish the job.

Ask two sets of questions.

Was the menopause side assessed?

• hot flashes or night sweats;
• cycle change;
• vaginal dryness, urinary symptoms, or painful sex;
• sleep disruption linked to heat episodes;
• age, menopause stage, uterus status, and risk history.

Was the depression side assessed?

• persistent low mood;
• loss of interest or pleasure;
• functional impairment;
• guilt, worthlessness, or hopelessness;
• thoughts of death or self-harm;
• past depression, bipolar, mania, or hypomania;
• substance use, major stress, and other medical causes.

A good appointment does not force you to choose which half is “real.” It assesses both.

You just narrowed this down. Lock it in. The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult. → Match my situation to the right starting point The tool may surface partner providers. The HRT Index may earn a commission if you start care through a partner link; that does not change the safety flags or matching criteria.

---

Does HRT itself affect mood?

Answer: It can, and not always in the direction you expected. The active PROMETRIUM label updated in July 2026 reports depression in 19% of women taking cyclic micronized progesterone with conjugated estrogens versus 12% on placebo. An archived 2010 repackaged label displays the estrogen-only arm from the same trial at 18%, so the table does not isolate progesterone as the cause.^[14][15]

This is our damaging admission, and we would rather you hear it here than find it later and wonder what else we skipped.

Most menopause marketing treats HRT as a mood rescue. The regulated label is more careful.

The Mood Line Ledger

The active PROMETRIUM label updated in July 2026 shows the combination and placebo columns from an 875-person, randomized, double-blind, placebo-controlled trial in postmenopausal women. An archived 2010 repackaged label displays all three arms from the same trial, including the conjugated-estrogens-only comparator. We are showing the versions together because that missing comparator changes the interpretation.^[14][15]

Adverse experience reported	Micronized progesterone 200 mg cyclically + conjugated estrogens 0.625 mg	Conjugated estrogens 0.625 mg alone — archived 2010 label	Placebo
Headache	31%	30%	27%
Breast tenderness	27%	16%	6%
Joint pain	20%	22%	29%
Depression	19%	18%	12%
Dizziness	15%	5%	9%

The archived 2010 repackaged label also carried a depression-monitoring instruction. That wording is not present in the active July 2026 label, so this page does not present it as current prescribing language.^[14][15]

What this does—and does not—prove

It does not prove that micronized progesterone causes depression.

The archived estrogen-only arm was nearly the same as the combination arm: 18% versus 19%. Depression was also reported by 12% of the placebo group. These reports cannot isolate progesterone as the cause, and they do not predict what will happen to you.

What it does prove is simpler:

“Just add hormones and you will feel better” is not the whole regulated story. Mood belongs in the monitoring plan.

That is not a reason to abandon HRT. It is a reason to stop pretending the only possible mood direction is up.

The pivot—why the downside makes the decision better

With an FDA-approved product, you can point to standardized labeling and a trial table—and you can see when current labeling has changed from an older archived version.

You can ask:

• Was the mood change new?
• Did it begin after estrogen, after the progestogen, or after a dose or route change?
• Did anything change in the antidepressant at the same time?
• Are hot flashes and sleep better while mood is worse?
• Does this look like a side effect, recurrence of depression, withdrawal, or something else?
• What is the safest next adjustment, and who owns it?

Do not turn a new low mood into a self-directed component swap. The honest next move is to ask whether the estrogen dose or route, progestogen, antidepressant, depression diagnosis, or another cause needs review.

Menopause hormone therapy does not come with a guaranteed mood benefit. If the main problem is diagnosed major depression, care that directly treats depression stays central. If HRT is being used for hot flashes, GSM, early menopause, or another defined menopause indication, mood still belongs in follow-up.

Current NICE guidance recommends reviewing menopause treatment at three months for efficacy and tolerability, then annually, with earlier review for ineffectiveness, side effects, or adverse events.^[11] New severe low mood, unsafe thoughts, or possible mania should not wait for a routine review.

What to record in the first three months

Write down:

• baseline mood before the first dose;
• hot flashes per day;
• whether a hot flash wakes you;
• sleep duration and whether you feel tired;
• new anxiety, agitation, or emotional flattening;
• bleeding;
• date of every HRT or antidepressant change;
• the exact component that changed.

Dates are more useful than adjectives.

---

How do I tell menopause from depression from a medication side effect?

Answer: You often cannot tell from the symptom alone because menopause, depression, HRT, and antidepressants overlap in sleep, energy, concentration, sweating, appetite, and sexual function. The pattern does not diagnose the cause; it gives the clinician something testable—especially when it is tied to medication, cycle, route, and symptom dates.

This is where women get stuck, and it is fixable with a notebook.

The Symptom Attribution Map

Symptom	Menopause-related possibilities	Depression or anxiety possibilities	Antidepressant possibilities	HRT-related possibilities	The detail worth recording
Broken sleep	Night sweats, temperature changes	Early waking, rumination, panic	Activation, sedation, sweating	May improve when VMS drive the waking; a regimen change can also alter sleep or mood	Did a heat surge wake you, or were you awake first?
Sweating	Hot flashes or night sweats	Panic or autonomic anxiety symptoms	Sweating is a recognized SSRI/SNRI effect[16]	Effective systemic HT should reduce VMS, but persistent sweating does not identify the cause	Sudden heat wave or steady dampness? Daytime too?
Fatigue	Repeated VMS and poor sleep	Depression itself	Sedation, sleep disruption, withdrawal	Could improve if sleep improves; could also begin around a regimen change	Time of day, dose time, and whether sleep changed first
Low desire or sexual difficulty	GSM, pain, dryness, sleep disruption	Depression, anxiety, relationship stress	SSRIs/SNRIs can affect desire and orgasm[16]	Vaginal or systemic estrogen can treat GSM symptoms; it does not guarantee desire, arousal, or orgasm	Is the problem desire, arousal, orgasm, dryness, or pain?
Foggy thinking	Sleep disruption and the menopause transition	Depression or anxiety	Sedation or other drug effects	HRT is not approved as a cognitive treatment; symptom change may track sleep or VMS	Does it move with sleep, heat episodes, or dose timing?
Low mood	Menopause-linked depressive symptoms	Major depression or another mood disorder	Adverse effect, activation, or discontinuation after a change	A mood change can follow a regimen change; the current label reports 19% versus 12%, while an archived label shows an 18% estrogen-only comparator	Exact onset date and whether pleasure, function, or safety changed
Agitation or feeling wired	Severe sleep disruption can amplify distress	Anxiety, mania, hypomania	Antidepressant activation, serotonin toxicity, withdrawal	Do not assume the hormone is the cause	Reduced need for sleep, racing thoughts, impulsivity, fever, tremor, or muscle rigidity
Nausea	Many non-menopause causes	Anxiety	Common antidepressant effect[16]	Can occur with some HRT products or routes	Start date, food, dose timing, severity, hydration
Bleeding	Perimenopausal cycle change	—	SSRIs can increase bleeding risk, especially with NSAIDs, antiplatelets, or anticoagulants[2]	Unscheduled bleeding can occur after starting or changing systemic HRT; persistent or postmenopausal bleeding requires evaluation	Amount, date, HRT start/change date, other bleeding-risk medicines

The right-hand column does not “tell them apart.” It stops four possible causes from collapsing into one vague sentence.

The two-week look-back

This is a tracking prompt, not a diagnostic rule:

Write down everything that changed in the two weeks before the symptom began.

• a new prescription;
• a dose increase or decrease;
• missed doses;
• a switch from patch to pill or one brand to another;
• a new supplement;
• a skipped cycle;
• a pharmacy backorder that changed the product;
• illness, alcohol change, major stress, or sleep loss.

A symptom that appeared two days after a medication change creates a different question from one that built over six months. Timing does not prove causation, but it makes the appointment readable.

One pattern means call today, not next month

If you have less need for sleep—not simply insomnia, but feeling rested on very little sleep—plus racing thoughts, unusual impulsiveness, markedly increased energy, grandiosity, or feeling wired and invincible, contact your prescriber the same day.

NIMH says antidepressants are not used alone in bipolar disorder because they can trigger a manic episode or rapid cycling.^[7]

If you are unsafe, psychotic, or unable to care for yourself, use urgent mental-health care, 988, or 911. That question outranks every hormone question on this page.

---

Do antidepressants work as well as HRT for hot flashes?

Answer: In one eight-week head-to-head trial, low-dose oral estradiol reduced vasomotor-symptom frequency by 52.9% and venlafaxine extended release by 47.6%, compared with 28.6% on placebo. The estradiol–venlafaxine difference was 0.6 episode per day and was not statistically significant; the trial did not establish that every antidepressant works like every HRT regimen.^[17]

This trial is useful because it compared a hormone and an antidepressant in the same population instead of asking you to compare numbers from different studies.

It is also easy to overread.

The MsFLASH trial randomized 339 perimenopausal and postmenopausal women with an average of 8.1 bothersome vasomotor symptoms per day to:

• oral 17β-estradiol 0.5 mg per day;
• venlafaxine extended release 75 mg per day after a one-week titration;
• placebo.

Treatment lasted eight weeks. The trial was designed to study VMS, not major depression, and excluded women with a major depressive episode in the previous year.^[17]

The head-to-head numbers

Result at week 8	Oral estradiol 0.5 mg	Venlafaxine ER 75 mg	Placebo
Mean vasomotor symptoms per day	3.9	4.4	5.5
Reduction from baseline	52.9%	47.6%	28.6%
Reduction beyond placebo	2.3 fewer per day	1.8 fewer per day	—
Treatment satisfaction	70.3%	51.1%	38.4%

Estradiol reduced symptoms by 0.6 more episode per day than venlafaxine, but the comparison had a P value of .09. The study authors called the difference small and of uncertain clinical relevance.^[17]

What this trial earns the right to say

• Venlafaxine is a legitimate, evidence-backed nonhormonal treatment for hot flashes.
• Low-dose oral estradiol and venlafaxine both outperformed placebo in this eight-week trial.
• The study gives a direct comparison for these exact products and doses.
• A woman offered an antidepressant for hot flashes has not automatically been diagnosed with depression. ACOG says that plainly.^[18]

What it does not earn the right to say

• Venlafaxine works as well as every form or dose of HRT.
• Every SSRI or SNRI performs like venlafaxine.
• The results apply to treatment of major depression.
• The satisfaction difference proves women preferred estradiol because of vaginal, sleep, bone, or sexual benefits. The trial did not establish the reason.
• An eight-week result settles long-term effectiveness or tolerability.
• Oral estradiol is the right route for you.

Systemic hormone therapy remains the most effective treatment for vasomotor symptoms overall when it fits the woman’s benefit-risk profile.^[13] But “most effective overall” does not make an antidepressant a fake menopause treatment.

Only one antidepressant has the FDA menopause indication

Low-dose paroxetine 7.5 mg, sold as Brisdelle, is FDA-approved for moderate-to-severe vasomotor symptoms associated with menopause. Its current label says it is not indicated for any psychiatric condition and recommends one 7.5 mg capsule at bedtime.^[2]

Other antidepressants used for VMS are prescribed off-label. Off-label does not mean unproven or improper; it means the FDA-approved label does not contain that specific indication.

We are not rebuilding the full nonhormonal comparison here. That would duplicate another decision and bury this one.

→ Compare nonhormonal hot-flash medications, FDA status, interaction flags, and current costs

---

Does my antidepressant rule out Veozah or Lynkuet?

Answer: Fluvoxamine rules out Veozah under the current FDA label because Veozah is contraindicated with any CYP1A2 inhibitor. Lynkuet uses a different interaction pathway: avoid strong CYP3A4 inhibitors, grapefruit, and strong or moderate CYP3A4 inducers; reduce the dose with a moderate CYP3A4 inhibitor.^[4][19]

These drugs are not hormones and are not antidepressants. They are prescription nonhormonal treatments for moderate-to-severe vasomotor symptoms due to menopause.

That makes them an obvious follow-up when a woman is already on an antidepressant—but the antidepressant still matters.

The Nonhormonal Cross-Check

Current labels verified: August 2026

Question	Veozah (fezolinetant)	Lynkuet (elinzanetant)
FDA-approved use	Moderate-to-severe VMS due to menopause	Moderate-to-severe VMS due to menopause
Standard labeled dose	45 mg once daily	120 mg at bedtime
Main interaction pathway	CYP1A2	CYP3A4
Absolute medication rule	Contraindicated with any CYP1A2 inhibitor—weak, moderate, or strong	Avoid strong CYP3A4 inhibitors and grapefruit; reduce to 60 mg with moderate CYP3A4 inhibitors; avoid strong and moderate CYP3A4 inducers
Antidepressant that creates the clearest flag	Fluvoxamine	Nefazodone is a strong CYP3A inhibitor in FDA’s examples table; St. John’s wort is a strong CYP3A inducer
Baseline liver tests	Required	Required
Follow-up liver tests	Monthly for the first 3 months, then at months 6 and 9	At 3 months
Other current label issue to know	Boxed warning for hepatotoxicity	CNS depression/daytime impairment; liver-enzyme elevations; pregnancy contraindication; seizure warning

Why the 840% number matters

In the Veozah label’s interaction study, fluvoxamine increased fezolinetant:

• peak concentration by 80%;
• total exposure by 840%.^[4]

This is not “mention it if you remember.” The label says Veozah is contraindicated with CYP1A2 inhibitors.

If you take fluvoxamine and someone suggests Veozah, use the exact word:

“I take fluvoxamine. The Veozah label says CYP1A2 inhibitors are contraindicated. Please check that before prescribing.”

Lynkuet is not the same workaround

Lynkuet was FDA-approved on October 24, 2025. Its current label uses the CYP3A4 pathway, not the CYP1A2 rule that blocks Veozah with fluvoxamine.^[19]

That does not make it a universal escape hatch.

The current label says:

• avoid strong CYP3A4 inhibitors and grapefruit;
• reduce the dose to 60 mg with a moderate CYP3A4 inhibitor;
• avoid strong and moderate CYP3A4 inducers;
• obtain baseline liver tests and repeat them at three months;
• use caution in people with seizure history or conditions that can lower the seizure threshold;
• account for somnolence, fatigue, vertigo, dizziness, and presyncope, which occurred in 11.9% on Lynkuet versus 3.5% on placebo across three trials.^[19]

Bupropion and the seizure question

Bupropion has a dose-related seizure warning. Lynkuet’s current label also warns about seizure risk and says to use caution when conditions can lower the seizure threshold.^[10][19]

That is not a label-listed contraindication between bupropion and Lynkuet.

It is a high-quality prescriber question:

“Both of these labels mention seizure risk. Does my dose, history, alcohol use, eating-disorder history, or any other medicine change whether this is appropriate?”

The damaging admission on newer drugs

A newer nonhormonal drug does not remove the need for medication review. It changes the interaction map.

Veozah creates a hard CYP1A2 line and a heavier liver-testing schedule. Lynkuet creates CYP3A4 rules, daytime-impairment concerns, a three-month liver check, and a current seizure warning.

The useful comparison is not “newer versus older.” It is which label fits your exact list and history.

---

What if I take tamoxifen?

Answer: Paroxetine has the clearest label-level tamoxifen warning on this page. Tamoxifen requires metabolic activation, including CYP2D6-mediated formation of endoxifen, and paroxetine strongly inhibits CYP2D6; current Brisdelle labeling says some studies found reduced tamoxifen effectiveness, others did not, and prescribers should weigh the risk and consider avoiding the combination.^[2][3]

Short section. High stakes.

The current tamoxifen label says the effect of strong CYP2D6 inhibitors on tamoxifen effectiveness is not fully established. It reports that some studies found reduced efficacy because active-metabolite levels fell, while other studies did not.^[3]

The current FDA CYP examples table classifies:

• paroxetine as a strong CYP2D6 inhibitor;
• fluoxetine as a strong CYP2D6 and CYP2C19 inhibitor;
• bupropion as a strong CYP2D6 inhibitor;
• sertraline and escitalopram as weak CYP2D6 inhibitors.^[5]

That does not authorize a consumer “safe swaps” list. Antidepressant choice for a woman taking tamoxifen is an oncology and pharmacy decision.

The Tamoxifen Handoff

What is true	What not to do	Who should own the next step
Paroxetine carries an explicit warning about possible reduced tamoxifen efficacy	Do not stop paroxetine or tamoxifen yourself	Oncologist plus the antidepressant prescriber and pharmacist
Fluoxetine and bupropion are strong CYP2D6 inhibitors in FDA’s examples table	Do not assume every strong inhibitor has identical outcome data	Oncology/pharmacy review of the exact regimen
Sertraline and escitalopram are listed as weak CYP2D6 inhibitors	Do not translate “weak” into “safe for me”	Prescriber chooses based on the full psychiatric and oncology picture
HRT in a hormone-sensitive cancer history is a separate decision	Do not let an interaction article decide hormone eligibility	Cancer-informed menopause care with the oncology team

If this is you, do not begin with a generic “Which online HRT provider?” intake as the only decision-maker.

Start with the oncology team and a pharmacist who can see the complete list. We would rather lose your click than route you badly.

---

Can HRT replace my antidepressant?

Answer: Not automatically. HRT is not FDA-approved as a treatment for perimenopausal depression, and diagnosed depression may still require antidepressant treatment, psychotherapy, or both. If the antidepressant was prescribed only for hot flashes, that creates a different review—but it still does not create permission to stop it alone.^[12][16]

There are two very different versions of this question.

“My antidepressant treats depression or anxiety”

HRT helping night sweats, sleep, or other menopause symptoms does not prove the psychiatric condition no longer needs treatment.

A deprescribing decision may depend on:

• why the antidepressant was started;
• number and severity of previous episodes;
• how long you have been stable;
• what happened during previous dose reductions;
• current stress and support;
• bipolar or mania history;
• the antidepressant’s discontinuation profile;
• whether another treatment is changing at the same time.

No percentage from another clinic can answer that for you.

“My antidepressant was prescribed only for hot flashes”

That is a more open conversation because the medication’s job is different.

Ask:

• Are the hot flashes now controlled by HRT?
• Is the antidepressant helping another symptom?
• What happened when it was started?
• What discontinuation symptoms are expected with this exact drug?
• What taper, if any, does the prescriber recommend?
• Which change happens first?
• What date will the result be reviewed?

The honest answer to “Will I be stuck on this forever?”

You may not be.

But the way to find out is a planned review, not a quiet taper.

FDA’s consumer guidance says not to stop depression medicine without first talking to the healthcare provider.^[16] Stopping suddenly can create discontinuation symptoms. If you feel awful afterward, you may be trying to separate withdrawal, recurrence of depression or anxiety, menopause symptoms, and a hormone change at the same time.

That is an experiment with no readable result.

The Antidepressant Review Grid

Question	If the answer is yes	What it changes
Was it prescribed for diagnosed depression, anxiety, or another psychiatric condition?	Keep the mental-health prescriber in the decision	HRT cannot be treated as an automatic replacement
Was it prescribed only for VMS?	Compare whether that target symptom is now controlled	A supervised medication review may be reasonable
Have you had recurrent or severe episodes?	Relapse prevention carries more weight	The decision is bigger than current symptom relief
Did you recently miss doses or reduce the dose?	Discontinuation may be part of the picture	Stabilize the timeline before attributing everything to menopause
Are two treatments changing at once?	Cause and effect will be harder to read	Ask whether nonurgent changes can be staged
Are there unsafe thoughts or possible mania?	Urgent assessment comes first	Do not wait for a routine hormone follow-up

Objection resolved: “I will be stuck on this forever.” You may not be. But the next step is a scheduled medication review with the person who prescribes it—not an unobserved taper. → Copy the three questions in the appointment section below

---

If I change both, which one should change first?

Answer: There is no universal HRT-first or antidepressant-first rule, and necessary mental-health treatment should never be delayed to create a cleaner experiment. When changes are nonurgent and the treating clinicians agree it is safe, changing one variable at a time can make benefit, side effects, and withdrawal easier to interpret.

We will be honest about what this section is:

It is an editorial planning principle, not a prescribing guideline.

If you start estradiol and change an SSRI dose in the same week, then sleep improves but mood flattens three weeks later, the timeline may not tell you which change did what.

Sometimes both changes still need to happen. Safety and urgency outrank clean attribution.

When a clean experiment does not matter

Do not delay:

• treatment for severe depression;
• response to suicidal thoughts;
• assessment of possible mania or psychosis;
• action on a contraindicated combination;
• care for a severe or rapidly worsening reaction;
• evaluation of unexplained postmenopausal bleeding;
• urgent cardiovascular or neurologic symptoms.

What a usable written plan contains

Put this in writing	Why it matters
Exact medicine, dose, and route changing	“HRT changed” is not specific enough
The target symptom	Defines what success means
Baseline count or description	Gives the follow-up a comparison point
Date of the change	Anchors every later symptom
What stays unchanged	Makes attribution more readable
Routine review date	Stops the plan from drifting
Early-call symptoms	Prevents a serious change from waiting
Who owns each medicine	Ends the “ask the other clinician” loop
What you must not change alone	Protects against a self-directed taper or dose escalation

For menopause treatment, current NICE guidance uses a three-month efficacy and tolerability review, then annual review, with earlier assessment for side effects or poor response.^[11] Your antidepressant review schedule depends on the drug, diagnosis, severity, and prescriber.

The One-Change Timeline

Use one row for every event:

Date	Medication or cycle change	Dose/route	Target symptom	What improved	What worsened	Who was told
Date	Start / stop / dose / brand / cycle	Exact dose or route	Target symptom	What improved	What worsened	Name and date

Bring dates to the appointment, not adjectives.

---

Who should coordinate HRT and antidepressant care?

Answer: One clinician should own the complete medication list and follow-up plan, even if different prescribers manage each drug. A menopause clinician can assess the HRT indication and route; the antidepressant prescriber should remain involved when it treats a psychiatric condition; a pharmacist can review the exact combination; and oncology should lead when tamoxifen or a hormone-sensitive cancer history is involved.

“Who can prescribe both?” is not always the right first question.

One clinician holding both prescriptions can reduce handoffs. It can also create false confidence if the service prescribes an SSRI for hot flashes but does not manage major depression, bipolar disorder, complex psychiatric medication, or cancer-treatment interactions.

The real question is:

Who owns each decision, and who can see the whole list?

The Care-Ownership Matrix

Person	What they should own	What not to assume
Menopause clinician or OB-GYN	Menopause stage, HRT indication, route, uterus/progestogen question, menopause-specific benefit-risk review, HRT follow-up	That they manage complex psychiatric diagnosis or antidepressant tapering
Primary care clinician	Whole-person differential, medication reconciliation, common medical causes, referrals, continuity	That every PCP has specialist menopause or psychiatric scope
Psychiatrist or antidepressant prescriber	Diagnosis, relapse history, antidepressant response, taper or dose change, bipolar/mania review	That they will independently assess HRT eligibility and route
Pharmacist	Exact drug–drug, supplement, OTC, dose, and label review	That a quick retail interaction alert replaces a clinical diagnosis or prescribing plan
Oncologist	Tamoxifen and cancer-treatment priorities; hormone-sensitive cancer context	That a general telehealth form can substitute for oncology coordination
Urgent mental-health service	Unsafe thoughts, psychosis, severe mania, inability to stay safe	That a routine HRT visit is the correct door today

What to verify before paying an online menopause service

This page is not publishing a volatile provider ranking for a mixed medical-and-psychiatric question. Before you pay, verify the service’s scope against your actual need.

Claim you may see	What to verify in writing	Why it matters
“We treat menopause mood symptoms”	Do they prescribe only for VMS/menopause symptoms, or do they diagnose and manage psychiatric conditions?	Menopause prescribing is not the same as psychiatry
“We offer FDA-approved and compounded HRT”	Which exact products are FDA-approved, which are compounded, and can you choose?	Those categories are not equivalent
“We coordinate care”	Will they send records or communicate with your existing prescriber?	Coordination needs an actual process
“Available in your state”	Is the relevant clinician licensed and the medication offered in your state?	A national landing page may not describe your checkout result
“Insurance accepted”	Is the visit in network, are medications separate, and what is your confirmed responsibility?	“Takes insurance” is not a price
“Ongoing support”	Follow-up cadence, messaging access, urgent-response boundaries, refill policy	“Unlimited support” can hide a narrow service
“We prescribe nonhormonal options”	Which ones, and do they handle their required labs and interaction rules?	Veozah and Lynkuet have distinct label requirements
“One clinician can handle everything”	Will that clinician also manage your existing antidepressant diagnosis and taper?	One account does not always mean one clinical scope

We review providers under The HRT Index Verification Standard: we read every published price, separate FDA-approved from compounded medications, verify state availability and insurance, and re-check on a fixed schedule—top providers monthly and the full roster quarterly.

The five pillars remain, in this order:

1. clinical legitimacy
2. care quality
3. medication fit
4. price transparency
5. access

We do not turn those pillars into an invented numeric score.

Objection resolved: “Who do I even ask?” Does this sound like your situation? Use Find My HRT Path to organize the menopause side of the decision, match your situation to an appropriate starting route, and flag when online care is not the right first door. → Find my HRT care route

---

What should I ask before my next prescription?

Answer: Three questions resolve most of the uncertainty faster than a general “Are these safe together?” Bring the exact generic names, doses, routes, indications, start dates, and every prescription, over-the-counter medicine, and supplement—the answer depends on the list, not the categories.

Copy these.

The three questions

#	Ask this	Why it works
1	“I take [antidepressant, dose, reason]. Does anything on my complete list change the hormone product and route you are suggesting?”	Forces the review beyond two drug names and makes route explicit
2	“Do my mood symptoms meet criteria for depression, or are we treating depressive symptoms that began with other menopause symptoms—and what is each medicine supposed to treat?”	Separates diagnosis from symptom overlap
3	“If my mood, sleep, bleeding, sweating, or sexual function changes, who do I call, what do we review first, and when is my routine follow-up?”	Creates ownership instead of reassurance

Add these when they apply

• “I take tamoxifen. Does my antidepressant inhibit CYP2D6 strongly enough to affect this plan?”
• “I take fluvoxamine. I understand Veozah is contraindicated with CYP1A2 inhibitors. Please check that before suggesting it.”
• “I take bupropion or have a seizure history. Does Lynkuet’s seizure warning change the plan?”
• “I take St. John’s wort.”
• “This is a compounded product. What are the exact ingredients and strengths, and why are we not using an FDA-approved option?”
• “I have a uterus. What is the endometrial-protection plan if the estrogen is systemic?”
• “What must I not stop or change without contacting you?”

Bring the list, not the category

Include:

• generic and brand names;
• dose;
• route;
• time of day;
• reason prescribed;
• start date;
• latest dose change;
• missed doses;
• prescriptions from every clinician;
• OTC pain medicines;
• supplements;
• alcohol or cannabis changes relevant to the review.

A pharmacist can often review an exact list and identify label-level interaction questions. Ask your pharmacy or health plan how to arrange the review and whether there is a consultation charge.

---

What are women actually trying to untangle?

Answer: The search is rarely just “Do these two drug classes interact?” Women are trying to separate withdrawal from relapse, menopause from depression, a hot-flash treatment from a psychiatric label, and a new hormone effect from a medication they had finally stabilized on.

We use forums for language and decision friction only—never as evidence that a treatment works, how often a side effect happens, or what is safe.

The questions are blunt because the situation is blunt:

• “HRT or Antidepressants or Both?” appears as the title of a public r/Perimenopause discussion.^[20]
• Women in r/Menopause describe the feeling that clinicians are comfortable prescribing antidepressants but reluctant to discuss HRT.^[21]
• Other threads ask how to know whether HRT or a different antidepressant is needed, or how to tell discontinuation symptoms from depression returning and perimenopause arriving at the same time.

That confusion is not irrational.

The symptoms overlap. The treatments can overlap. The prescribers may be separate. And starting one medication can change how the other medication’s benefits or drawbacks feel.

You should not have to choose between being believed about menopause and staying stable in your mental-health care.

Both halves can be real. Both deserve a proper assessment.

---

What did The HRT Index actually verify?

Answer: We checked current FDA and DailyMed labeling for oral estradiol, micronized progesterone, Brisdelle, tamoxifen, Veozah, Lynkuet, and bupropion; FDA’s CYP examples; current NICE menopause guidance; The Menopause Society’s hormone-therapy guidance; and the published estradiol-versus-venlafaxine trial. We did not review your list, clinically review this article, or verify a provider price for this page.

We checked	We are not claiming
The oral estradiol label’s CYP3A4 language and named examples	That the named examples are a complete interaction list
FDA’s current CYP examples and FDA’s warning that the table is not comprehensive	That omission from the table proves no interaction
The active July 2026 PROMETRIUM table: 19% combination versus 12% placebo, plus the archived 2010 repackaged label showing the same trial’s 18% estrogen-only arm	That progesterone caused the depression reports, or that archived wording remains current
Current NICE recommendations for subthreshold depressive symptoms, diagnosed depression, and three-month review	That NICE created an HRT-first rule for major depression
The U.S. perimenopausal-depression guideline	That estrogen is FDA-approved for depression
Brisdelle’s VMS indication, 7.5 mg labeled dose, and tamoxifen warning	That every paroxetine product has the same indication or dose
Tamoxifen’s CYP2D6-inhibitor uncertainty	A consumer “safe antidepressant swap” list
Veozah’s CYP1A2 contraindication, 840% fluvoxamine exposure increase, boxed liver warning, and lab schedule	That every antidepressant rules out Veozah
Lynkuet’s current CYP3A4 rules, liver testing, CNS effects, and seizure warning	That bupropion plus Lynkuet is a listed contraindication
The MsFLASH estradiol-versus-venlafaxine trial	That the result applies to every HRT route, antidepressant, or depression treatment
FDA’s position on compounded “bioidentical” hormones	That a compounded preparation is equivalent to an FDA-approved product
The exact identity and care-routing framework used on this page	Your eligibility, diagnosis, dose, interaction clearance, or outcome

How this page was made

Editorial research by The HRT Index, with AI-assisted drafting. Medical and regulatory statements were checked against the cited sources on the verification date at the top.

This article has not been reviewed by a clinician. We are not adding a person’s name or credentials to create authority that did not exist.

Where a source established only a pathway, we called it a pathway. Where a label gave a contraindication, we used the word contraindicated. Where a trial could not prove cause, we did not turn association into cause.

When this page will be rechecked

Element	Refresh cadence	Trigger
FDA/DailyMed drug labels	Quarterly, plus alerts	New safety communication, contraindication, dosage, or interaction change
Veozah and Lynkuet requirements	Monthly during active label changes	New boxed warning, testing schedule, interaction rule, or postmarketing update
FDA CYP examples table	Quarterly	Table revision or classification change
NICE and U.S. depression guidance	Twice yearly	New guideline, amendment, or major society statement
Internal medication-comparison link	Monthly	Slug, price, FDA-status, or page-scope change
Find My HRT Path routing logic	Monthly for safety flags	Any source or eligibility rule changes
Page date	Only after substantive re-verification	The sources and affected copy were actually rechecked

---

What else should I know about HRT and antidepressants?

Answer: Brand-specific pairings still depend on the exact hormone product and route, antidepressant dose and indication, other medicines, supplements, and history. The answers below identify the strongest current label and guideline flags; they do not declare a personal combination safe or tell you to change medication.

Can I take HRT and sertraline together?

Sertraline and HRT can appear in the same treatment plan. FDA’s current CYP examples table classifies sertraline as a weak CYP2D6 inhibitor and does not classify it as a CYP3A inhibitor or inducer; the oral estradiol label reviewed does not name sertraline among its CYP3A4 examples.^[5][6]

That is reassuring but narrower than a clearance. Ask a pharmacist or prescriber to review the exact hormone product, sertraline dose and indication, other prescriptions, OTC medicines, supplements, and history.

Can I take HRT and escitalopram or Lexapro together?

The same narrow answer applies. FDA’s examples table lists escitalopram as a weak CYP2D6 inhibitor, not a CYP3A inhibitor or inducer, and it is not one of the named CYP3A4 examples in the reviewed oral estradiol label.^[5][6]

The complete list still decides. Escitalopram’s own label, other medicines, bleeding-risk drugs, and psychiatric history remain part of the review.

Can I take HRT and venlafaxine or Effexor together?

They can be used for different targets in the same care plan: HRT may treat a menopause indication while venlafaxine treats depression, anxiety, or off-label VMS. Venlafaxine also has direct head-to-head VMS data against low-dose oral estradiol, but that trial did not test taking the two together.^[17]

Do not use the trial as an interaction clearance. Review blood pressure, side effects, the exact HRT route, and the complete medication list.

Can I take HRT and bupropion or Wellbutrin together?

The reviewed oral estradiol label does not name bupropion among its CYP3A4 examples. FDA’s CYP table classifies bupropion as a strong CYP2D6 inhibitor, which makes tamoxifen a priority review flag.^[5]

Bupropion also has a dose-related seizure warning. If Lynkuet is being considered, ask about the fact that both labels contain seizure-related precautions rather than assuming the combination is prohibited or harmless.^[10][19]

Can I take HRT and fluoxetine or Prozac together?

Fluoxetine is not named among the reviewed oral estradiol label’s CYP3A4 examples. FDA’s examples table classifies it as a strong CYP2D6 and CYP2C19 inhibitor.^[5][6]

If tamoxifen is anywhere in the picture, bring that combination to oncology and pharmacy review. Do not stop fluoxetine yourself.

Will HRT stop my antidepressant from working?

The sources reviewed do not establish a class-wide effect in which menopausal HRT stops common antidepressants from working. That does not mean your symptoms cannot change after HRT starts.

Sleep, sweating, sexual function, mood, bleeding, and side effects can shift even without a direct pharmacokinetic interaction. Track the timeline and ask what each medicine is supposed to treat.

Can HRT replace my antidepressant?

Not automatically. Estrogen is not FDA-approved to treat perimenopausal depression, and antidepressants and psychotherapy remain established treatments for diagnosed depression.^[12]

If the antidepressant was prescribed only for hot flashes, that changes the review. It does not remove the need for the prescriber to plan any taper or discontinuation.

Does estrogen help depression?

A U.S. expert-panel guideline found evidence of antidepressant effects in some perimenopausal women, particularly when vasomotor symptoms coexist, while concluding that estrogen did not treat depressive disorders in postmenopausal women. Estrogen is not FDA-approved for perimenopausal depression, and data for estrogen plus progestogen were sparse and inconclusive.^[12]

Stage matters. Diagnosis, severity, history, and the symptom HRT is meant to treat matter too.

Does progesterone cause depression?

The active PROMETRIUM label does not prove that. It reports depression in 19% of women taking cyclic micronized progesterone with conjugated estrogens versus 12% on placebo. An archived 2010 repackaged label displays the estrogen-only arm from the same trial at 18%.^[14][15]

The nearly identical 19% combination and 18% estrogen-only reports do not isolate progesterone as the cause. The old repackaged label carried a depression-monitoring instruction, but that wording is not in the active July 2026 label.

Can I take HRT and paroxetine or Paxil together?

Paroxetine is not named among the reviewed oral estradiol label’s CYP3A4 examples. FDA’s CYP examples table classifies paroxetine as a strong CYP2D6 inhibitor, which makes tamoxifen the priority medication flag.^[2][5][6]

Brisdelle is a 7.5 mg paroxetine product labeled for menopausal VMS and is not indicated for a psychiatric condition. Do not substitute one paroxetine product or dose for another, and do not stop paroxetine without its prescriber.

Can HRT make my antidepressant work better?

Not predictably. A U.S. expert-panel guideline found possible antidepressant effects from estrogen in selected perimenopausal women—especially when VMS coexist—but it did not establish a class-wide antidepressant-augmentation effect, and estrogen is not FDA-approved for perimenopausal depression.^[12]

HRT should have its own defined menopause indication. A change in depression treatment still belongs with the clinician managing the depression.

Should I try HRT before an antidepressant?

There is no universal HRT-first rule. NICE says to consider HRT when depressive symptoms do not meet criteria for depression and began with other menopause symptoms; when depression is suspected or diagnosed, menopause and depression guidance should be used together.^[11]

Established or urgent depression treatment should not be delayed to create an HRT trial. The decision starts with diagnosis, symptom target, severity, history, and safety—not a fixed sequence.

Can HRT reverse sexual side effects from an antidepressant?

HRT can treat menopause-related vaginal dryness and painful sex when it is appropriate, but that is not the same as reversing an SSRI or SNRI effect on desire or orgasm. FDA lists sexual problems among common SSRI and SNRI effects.^[8][16]

Name the exact problem—desire, arousal, orgasm, dryness, or pain—because each points to a different review. Do not assume adding estrogen will cancel an antidepressant side effect.

Do HRT and antidepressants cause weight gain when taken together?

The reviewed sources do not establish a predictable combined weight-gain effect from taking HRT with an antidepressant. Antidepressants differ: FDA’s consumer guidance lists weight gain for mirtazapine, while other classes have different appetite and weight profiles; The Menopause Society says hormone therapy should not be used to manage weight gain.^[16][22]

Track the trend, appetite, swelling, sleep, activity, and the date of each medication change. Review the exact product labels rather than treating both drug classes as one weight effect.

Can I take St. John’s wort with HRT?

Tell the prescriber or pharmacist before combining them. Current oral estradiol labeling names St. John’s wort as a CYP3A4 inducer that may lower estrogen concentrations, reduce therapeutic effect, or change uterine bleeding.^[6]

The effect can vary by St. John’s wort preparation. It can also interact with antidepressants and other medicines, so it belongs on the full list.

Can I take Veozah with my antidepressant?

It depends on the exact antidepressant. Veozah is contraindicated with any CYP1A2 inhibitor, and fluvoxamine is a strong CYP1A2 inhibitor; in the label study, fluvoxamine increased fezolinetant total exposure by 840%.^[4][5]

Other antidepressants may create different issues through their own labels or the rest of your list. Ask directly rather than assuming.

Can antidepressants cause night sweats?

Sweating is a recognized effect listed in FDA’s consumer guidance for antidepressants.^[16] Menopausal VMS, panic, infection, other medicines, and other medical causes can also produce sweating.

A sudden heat surge, daytime symptoms, dose timing, and the start date give the clinician useful clues. They do not diagnose the cause by themselves.

Does HRT cause serotonin syndrome?

Menopausal HRT is not presented in the reviewed sources as a general cause of serotonin syndrome. The relevant warning usually comes from an antidepressant combined with another serotonergic drug or an MAOI.

Current Brisdelle labeling lists serotonergic combinations and contraindicates MAOIs. Give the prescriber every prescription, migraine medicine, opioid, supplement, and OTC product rather than checking estrogen alone.^[2]

How long before I know whether HRT is helping my mood?

There is no universal mood-response clock because HRT is not an FDA-approved depression treatment and the target may be sleep, VMS, or another menopause symptom. Current NICE guidance recommends a menopause-treatment review at three months for efficacy and tolerability, sooner if side effects or adverse events appear.^[11]

Track mood, function, sleep, VMS, bleeding, and every medication change from day one. Do not wait three months for severe worsening, unsafe thoughts, or possible mania.

My doctor will not discuss HRT. What now?

Ask which diagnosis and symptom target support the current plan, and whether menopause stage, hot flashes, vaginal or urinary symptoms, sleep, cycle change, medication effects, and relevant medical causes were assessed.

That is a fair question, not a confrontation. If the answer still does not address the menopause side, a second opinion from a menopause-focused clinician may be reasonable. Urgent psychiatric or oncology issues still take priority when present.

---

What is the bottom line on HRT and antidepressants?

Answer: HRT and antidepressants can be prescribed together, but no category-level answer clears your exact combination. Your hormone product and route, antidepressant and indication, other medicines, mood history, and follow-up plan determine the review—and stopping or tapering an antidepressant remains a prescriber decision.

You came here with a two-drug question. Here is the whole page in seven lines:

1. HRT and antidepressants can be prescribed together, but the categories cannot clear your combination.
2. The exact hormone product, route, antidepressant, indication, full medication list, and history decide the review.
3. St. John’s wort is named in the oral estradiol label; fluvoxamine makes Veozah contraindicated; paroxetine creates a tamoxifen warning.
4. Menopause-linked depressive symptoms below the depression threshold are not the same question as diagnosed major depression.
5. The current progesterone label reports 19% combination versus 12% placebo; an archived label shows the estrogen-only arm at 18%. Monitor—do not invent a cause.
6. When changes are nonurgent, a written one-change-at-a-time plan can make the result easier to read. Safety comes first.
7. Do not stop or taper your antidepressant on your own.

You do not have to choose between being taken seriously about menopause and staying stable in your mental health.

Both halves are real. Both deserve a proper look.

Still not sure which HRT program is right for you? Take our free 90-second matching quiz.

→ Find My HRT Path — match your symptoms, route preference, risk history, insurance or cash-pay situation, and state to the right starting route, with a flag when online care is not your right first step.

---

Educational editorial research only—not medical advice, a diagnosis, an interaction clearance, or a substitute for your prescriber or pharmacist. FDA-approved and compounded medications are labeled separately throughout this page; compounded products are not presented as equivalent to FDA-approved products.

¹ 988 Suicide & Crisis Lifeline — What to Expect

² FDA prescribing information for BRISDELLE (paroxetine), 2025 label

³ DailyMed prescribing information for SOLTAMOX (tamoxifen)

⁴ DailyMed prescribing information for VEOZAH (fezolinetant)

⁵ FDA — Examples of Drugs that Interact with CYP Enzymes and Transporter Systems

⁶ DailyMed prescribing information for oral estradiol tablets

⁷ National Institute of Mental Health — Bipolar Disorder

⁸ The Menopause Society — Hormone Therapy

⁹ FDA — Menopause: compounded “bioidentical” hormones

¹⁰ DailyMed prescribing information for bupropion hydrochloride extended-release tablets

¹¹ NICE NG23 — Menopause: identification and management, recommendations, updated April 2026

¹² Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression

¹³ The Menopause Society — 2022 Hormone Therapy Position Statement summary

¹⁴ DailyMed active prescribing information for PROMETRIUM (micronized progesterone), updated July 2026

¹⁵ DailyMed archived 2010 repackaged PROMETRIUM label displaying the three trial arms

¹⁶ FDA — Depression Medicines

¹⁷ Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and venlafaxine for vasomotor symptoms: randomized clinical trial

¹⁸ ACOG — Can antidepressants help treat menopausal symptoms?

¹⁹ DailyMed prescribing information for LYNKUET (elinzanetant)

²⁰ Reddit r/Perimenopause — “HRT or Antidepressants or Both?”

²¹ Reddit r/Menopause discussion about clinicians prescribing antidepressants but not HRT

²² The Menopause Society — Statement on hormone-therapy misinformation